Biocytogen Enters into Collaboration with Moonlight Bio to Advance Cell Therapy Development for Difficult Cancers
Tuesday, March 24, 2026
Biocytogen Pharmaceuticals has announced a strategic collaboration with Moonlight Bioto support the development of advanced cell therapies targeting difficult-to-treat cancers.
Under the agreement, Biocytogen will provide its off-the-shelf library of fully human antibody binders directed at selected therapeutic targets. These binders are expected to support the design and development of novel cell therapy candidates. Moonlight Bio will be responsible for the preclinical development and advancement of these therapies.
The collaboration aims to accelerate the development timeline by combining ready-to-use antibody resources with specialised cell therapy expertise. This approach may help address current limitations in cancer treatment, including resistance to existing therapies and limited effectiveness in certain patient populations.
The partnership also reflects the growing role of antibody-based technologies beyond traditional drug formats, particularly in enabling more targeted and adaptable cell therapy strategies.
Source: biocytogen.com
